Hangzhou ThinHeal Pharma-Tech Co., Ltd.: GLP-1 import refusal records

Has FDA refused imports of GLP-1 products from Hangzhou ThinHeal Pharma-Tech Co., Ltd.?

Yes. FDA’s import refusal records list 2 refused shipment lines declared as made by Hangzhou ThinHeal Pharma-Tech Co., Ltd. (China) whose FDA product code names semaglutide and tirzepatide, on May 1, 2025. 2 of them carry a product code that FDA’s Import Alert 66-80 lists as a GLP-1 API or powder form.

Country
China
City in FDA records
Qiantang District, Hangzhou
FEI numbers on the lines
3033182388
Refused lines
2
Lines with an Import Alert 66-80 API or powder code
2
Drugs named in the product codes
Semaglutide, Tirzepatide
Refusal dates
May 1, 2025

The declared manufacturer is the firm named on the import entry. A refusal is FDA’s decision on one shipment line; it is not a finding about the firm’s other products.

Import Alert 66-80’s Green List (published Oct 9, 2026) prints a redaction in place of every firm name, so this index cannot say whether Hangzhou ThinHeal Pharma-Tech Co., Ltd. is on it.

Refused shipment lines

FDA refusal chargesShipment ID
May 1, 2025China61PCT72 SEMAGLUTIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
BYA-2501606-4/12/1
May 1, 2025China61PCT74 TIRZEPATIDE (ANTI-DIABETIC)Active Pharm Ingred/Chems for Rx CompoundingNOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).
FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.
BYA-2501606-4/12/2

FDA refusal charges on these lines

A line can carry several charges. Text is FDA’s charge statement, verbatim.

NOT LISTED: The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information available to the FDA, it appears that the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by 510(j) or 510(k).2
FRNMFGREG: The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, it appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under Section 510 of the Act.2

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.

2 lines from FDA files read Nov 15, 2026.